Scarica l'app Stockscreener
226.88
1.61%
-3.71
Pre-mercato:
230.00
3.12
+1.38%
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint - simplywall.st
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with Strong Buy Ratings and 11% Potential Upside - DirectorsTalk Interviews
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P - GuruFocus
Jazz Pharmaceuticals (JAZZ) Shares Decline After Zepzelca Trial Results - GuruFocus
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity - Stock Titan
Jazz Pharmaceuticals lung cancer drug fails late-stage trial By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ) Reports Phase 3 Trial Results for Ze - GuruFocus
Jazz Pharmaceuticals' Zepzelca misses primary goal in Phase 3 LAGOON trial - grafa.com
Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
Jazz Pharmaceuticals stock falls after lung cancer trial fails By Investing.com - Investing.com Australia
Jazz Pharmaceuticals stock falls after lung cancer trial fails - Investing.com
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial By Investing.com - Investing.com Australia
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial - Investing.com
Jazz Pharma's lung cancer drug fails late-stage trial - marketscreener.com
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PR Newswire
MIdWestOne Financial Group Inc. Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
UBS upgrades Jazz Pharmaceuticals (JAZZ) - MSN
New Xywav Data And FDA Ruling Put Jazz Valuation In Focus - Yahoo Finance
Daiwa Securities Group Inc. Has $1.46 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Allianz Asset Management GmbH Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst - Benzinga
JAZZ Maintained by B of A Securities -- Price Target Raised to $307 - GuruFocus
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $259.28, Implies 13% Upside - TradingView
GW&K Investment Management LLC Sells 27,068 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
BofA raises Jazz Pharmaceuticals stock price target on Ziihera sales By Investing.com - Investing.com UK
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Franklin Resources Inc. - MarketBeat
Bernstein SocGen reiterates Jazz Pharmaceuticals stock rating at Market Perform - Investing.com UK
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential - ChartMill
Truist assumes Jazz Pharmaceuticals stock with buy on oncology growth By Investing.com - Investing.com UK
Jazz Pharmaceuticals plc ($JAZZ) President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
Jazz Pharmaceuticals (JAZZ) sets 2026 AGM on directors, pay and share issuance powers - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Los Angeles Capital Management LLC - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Navigating a 6.14% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Capital World Investors Has $453.32 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
CenterBook Partners LP Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly Results - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Public Limited Company Trade Ideas — XETR:J7Z - TradingView
Bank of New York Mellon Corp Purchases 715,361 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (NASDAQ: JAZZ) CEO donates 600 shares - Stock Titan
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - marketscreener.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge - ChartMill
Globeflex Capital L P Takes $780,000 Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ News | JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) - ChartMill
Jazz Pharmaceuticals surges on earnings beat, strong revenue By Investing.com - Investing.com Australia
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report? - Yahoo Finance
Jazz to present 21 abstracts on Xywav at sleep conference By Investing.com - Investing.com Australia
Jazz to present 21 abstracts on Xywav at sleep conference - Investing.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):